Ertapenem

Ertapenem Dosage

Dosing: Adult I.M., I.V.: 1 g/day; duration of total antibiotic treatment: 10-14 days

Note: I.V. therapy may be administered for up to 14 days; I.M. for up to 7 days

Community-acquired pneumonia and complicated urinary tract infections (including pyelonephritis):

I.M., I.V.: 1 g/day; duration of total antibiotic treatment: 10-14 days

(Note: Duration includes possible switch to appropriate oral therapy after at least 3 days of parenteral treatment,

once clinical improvement demonstrated.)

Intra-abdominal infection: I.M., I.V.: 1 g/day for 5-14 days;

Note: 2010 IDSA guidelines recommend a treatment duration of 4-7 days

(provided source controlled) for community-acquired, mild-to-moderate IAI

Pelvic infections (acute): I.M., I.V.: 1 g/day for 3-10 days

Prophylaxis of surgical site following colorectal surgery: I.V.: 1 g given 1 hour preoperatively

Skin and skin structure infections (including diabetic foot infections): I.M., I.V.: 1 g/day for 7-14 days

Dosing: Pediatric

Note: I.V. therapy may be administered for up to 14 days; I.M. therapy for up to 7 days

Children 3 months to 12 years:

Community-acquired pneumonia and complicated urinary tract infections (including pyelonephritis):

I.M., I.V.: 15 mg/kg twice daily (maximum: 1 g/day); duration of total antibiotic treatment: 10-14 days

(Note: Duration includes possible switch to appropriate oral therapy after at least 3 days of parenteral treatment,

once clinical improvement demonstrated.)

Intra-abdominal infection: I.M., I.V.: 15 mg/kg twice daily (maximum: 1 g/day) for 5-14 days

Pelvic infections (acute): I.M., I.V.: 15 mg/kg twice daily (maximum: 1 g/day) for 3-10 days

Skin and skin structure infections: I.M., I.V.: 15 mg/kg twice daily (maximum: 1 g/day) for 7-14 days

Children ≥13 years: Refer to adult dosing.

Dosing: Geriatric

Refer to adult dosing.

Dosing: Renal Impairment

Children: No data available for pediatric patients with renal insufficiency.

Adults:

Clcr >30 mL/minute/1.73 m2: No adjustment required

Clcr ≤30 mL/minute/1.73 m2 and ESRD: 500 mg/day

Hemodialysis: When the daily dose is given within 6 hours prior to hemodialysis, a supplementary dose of 150 mg is required following hemodialysis

Ertapenem Brands

Brand Name Manufacturer Name Distributor Drug Strength Packaging Formulation Formulation Strength Price
invanz MSD 1g powder Injection per vial KES 8,760.00